For drugs exhibiting poor pharmacokinetics, limited bioavailability and a high degree of toxicity, there is growing interest in the field of nano-medicine and the biocompatibility performance of liposomes and lipid nanoparticles.
Because of the amphiphilic phospholipid bilayer’s resemblance to the mammalian cell membrane, liposomes and lipid nanoparticles (LNPs) are able to shield a drug from detection by the immune system, allowing additional time to get to the point of need without triggering an immune response. This capability makes liposomes and lipid nanoparticles particularly suitable for the delivery of DNA and mRNA payloads for vaccines.
Download the online exclusive to read more >>>>>